Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2011-004457-87Phase 3
Phase 3, randomised, single-blind trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoint: Primary seroprotection rates for hepatitis B and PRP.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2011-004457-87.